Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study
Lari Wenzel(University of California, Irvine), Richard P. Moser(National Cancer Institute), Michael Friedländer(Prince of Wales Hospital), Gustavo C. Rodriguez(NorthShore University HealthSystem), Helen Huang(Roswell Park Comprehensive Cancer Center), Jamie N. Bakkum‐Gamez(Mayo Clinic in Arizona), Martee L. Hensley(Memorial Sloan Kettering Cancer Center), John F. Boggess(University of Kentucky), Robert M. Wenham(Moffitt Cancer Center), Joan L. Walker(Cornell University), Alexander Olawaiye(Magee-Womens Hospital), Paul K. J. Han(National Cancer Institute), Oliver Zivanovic(Memorial Sloan Kettering Cancer Center), Mark H. Greene(Cancer Institute (WIA)), David E. Cohn(The Ohio State University), Chad A. Hamilton(Inova Health System), Marion Piedmonte(Cleveland Clinic), Thomas Rutherford(University of South Florida), J.T. Thigpen(Nova Southeastern University)
Cited by 1
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k